Future development of amifostine in cancer treatment

David S Alberts, W. A. Bleyer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Amifostine selectively protects normal, but not tumor, tissue from the cytotoxic damage induced by radiation therapy and chemotherapy. In a broad range of preclinical and phase II and III clinical studies, amifostine has been shown to substantially reduce anticancer drug-induced neutropenia, thrombocytopenia, nephrotoxicity, neurotoxicity (including ototoxicity and peripheral neuropathy), musculoskeletal toxicity, cardiotoxicity, and mutagenicity. Based on the rapidly expanding clinical trials database, there is strong rationale to design phase II and III studies of amifostine as a cytoprotective agent in patients with early and/or advanced breast, bladder, cervix, head and neck, small cell and nonsmall cell lung, ovarian, and rectal cancers, as well as melanoma, pediatric sarcomas, and lymphomas, including Hodgkin's disease. In this article, we have attempted to survey recently completed and ongoing phase II and III clinical studies and suggest specific designs for future clinical trials to establish the ultimate role of amifostine as a broad-spectrum cytoprotective agent.

Original languageEnglish (US)
Pages (from-to)90-99
Number of pages10
JournalSeminars in Oncology
Volume23
Issue number4 SUPPL. 8
StatePublished - 1996

Fingerprint

Amifostine
Neoplasms
Clinical Trials
Proxy
Peripheral Nervous System Diseases
Therapeutics
Rectal Neoplasms
Neutropenia
Hodgkin Disease
Cervix Uteri
Non-Small Cell Lung Carcinoma
Sarcoma
Thrombocytopenia
Ovarian Neoplasms
Melanoma
Lymphoma
Urinary Bladder
Breast
Neck
Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Future development of amifostine in cancer treatment. / Alberts, David S; Bleyer, W. A.

In: Seminars in Oncology, Vol. 23, No. 4 SUPPL. 8, 1996, p. 90-99.

Research output: Contribution to journalArticle

Alberts, DS & Bleyer, WA 1996, 'Future development of amifostine in cancer treatment', Seminars in Oncology, vol. 23, no. 4 SUPPL. 8, pp. 90-99.
Alberts, David S ; Bleyer, W. A. / Future development of amifostine in cancer treatment. In: Seminars in Oncology. 1996 ; Vol. 23, No. 4 SUPPL. 8. pp. 90-99.
@article{60b5cbf7a66b47fabed62ba4a7a5e177,
title = "Future development of amifostine in cancer treatment",
abstract = "Amifostine selectively protects normal, but not tumor, tissue from the cytotoxic damage induced by radiation therapy and chemotherapy. In a broad range of preclinical and phase II and III clinical studies, amifostine has been shown to substantially reduce anticancer drug-induced neutropenia, thrombocytopenia, nephrotoxicity, neurotoxicity (including ototoxicity and peripheral neuropathy), musculoskeletal toxicity, cardiotoxicity, and mutagenicity. Based on the rapidly expanding clinical trials database, there is strong rationale to design phase II and III studies of amifostine as a cytoprotective agent in patients with early and/or advanced breast, bladder, cervix, head and neck, small cell and nonsmall cell lung, ovarian, and rectal cancers, as well as melanoma, pediatric sarcomas, and lymphomas, including Hodgkin's disease. In this article, we have attempted to survey recently completed and ongoing phase II and III clinical studies and suggest specific designs for future clinical trials to establish the ultimate role of amifostine as a broad-spectrum cytoprotective agent.",
author = "Alberts, {David S} and Bleyer, {W. A.}",
year = "1996",
language = "English (US)",
volume = "23",
pages = "90--99",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 8",

}

TY - JOUR

T1 - Future development of amifostine in cancer treatment

AU - Alberts, David S

AU - Bleyer, W. A.

PY - 1996

Y1 - 1996

N2 - Amifostine selectively protects normal, but not tumor, tissue from the cytotoxic damage induced by radiation therapy and chemotherapy. In a broad range of preclinical and phase II and III clinical studies, amifostine has been shown to substantially reduce anticancer drug-induced neutropenia, thrombocytopenia, nephrotoxicity, neurotoxicity (including ototoxicity and peripheral neuropathy), musculoskeletal toxicity, cardiotoxicity, and mutagenicity. Based on the rapidly expanding clinical trials database, there is strong rationale to design phase II and III studies of amifostine as a cytoprotective agent in patients with early and/or advanced breast, bladder, cervix, head and neck, small cell and nonsmall cell lung, ovarian, and rectal cancers, as well as melanoma, pediatric sarcomas, and lymphomas, including Hodgkin's disease. In this article, we have attempted to survey recently completed and ongoing phase II and III clinical studies and suggest specific designs for future clinical trials to establish the ultimate role of amifostine as a broad-spectrum cytoprotective agent.

AB - Amifostine selectively protects normal, but not tumor, tissue from the cytotoxic damage induced by radiation therapy and chemotherapy. In a broad range of preclinical and phase II and III clinical studies, amifostine has been shown to substantially reduce anticancer drug-induced neutropenia, thrombocytopenia, nephrotoxicity, neurotoxicity (including ototoxicity and peripheral neuropathy), musculoskeletal toxicity, cardiotoxicity, and mutagenicity. Based on the rapidly expanding clinical trials database, there is strong rationale to design phase II and III studies of amifostine as a cytoprotective agent in patients with early and/or advanced breast, bladder, cervix, head and neck, small cell and nonsmall cell lung, ovarian, and rectal cancers, as well as melanoma, pediatric sarcomas, and lymphomas, including Hodgkin's disease. In this article, we have attempted to survey recently completed and ongoing phase II and III clinical studies and suggest specific designs for future clinical trials to establish the ultimate role of amifostine as a broad-spectrum cytoprotective agent.

UR - http://www.scopus.com/inward/record.url?scp=0029761498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029761498&partnerID=8YFLogxK

M3 - Article

C2 - 8783674

AN - SCOPUS:0029761498

VL - 23

SP - 90

EP - 99

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 8

ER -